Intradialytic hypotension frequency is reduced by levocarnitine supplementation
Parole chiave:Carnitine, Hemodialysis, Intradialytic hypotension
Introduction: Intradialytic hypotension (IDH) is a frequent complication of hemodialysis. IDH causes intradialytic discomfort and subclinical ischemia, resulting in a higher rate of morbidity and mortality. Levocarnitine (LC) administration has been suggested for the treatment of IDH, but conflicting reports about its efficacy have been published. We describe the effect of LC supplementation in patients experiencing recurrent IDH episodes, in spite of common strategies used to prevent it.
Methods: Sixteen hemodialysis patients were studied. IDH was defined as a drop in systolic blood pressure ≥20 mmHg, with or without symptoms, prompting an intervention by the dialysis staff, such as reducing/stopping ultrafiltration rate and/or fluid administration. Blood pressure was recorded for 192 hemodialysis sessions, before LC supplementation. Thereafter LC (30 mg/kg dry weight) was administered at the beginning of each hemodialysis, registering blood pressure for 384 hemodialysis treatments. The difference between the predialysis systolic blood pressure and the minimum systolic blood pressure of each hemodialysis was evaluated (∆SBP), before and after LC supplementation. Cardiac ejection fraction was also measured.
Results: Predialysis and postdialysis systolic, diastolic, and mean arterial pressures did not differ before and after LC supplementation. Before LC supplementation, 36 episodes of IDH occurred (19%), while after LC supplementation, the IDH episodes were 29 during 384 hemodialysis sessions (8%; χ2 = 16.03; p = 0.0001). ∆SBP was lower after LC supplementation, even though the difference was not significant (p = 0.22).
Conclusion: IDH frequency was significantly reduced by predialysis LC supplementation, which can be helpful for patients’ well-being and reduction in IDH-associated risks.
Kanbay M, Ertuglu LA, Afsar B, et al. An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. Clin Kidney J. 2020;13(6):981-993. https://doi.org/10.1093/ckj/sfaa078 PMID:33391741
Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. 2015;26(3):724-734. https://doi.org/10.1681/ASN.2014020222 PMID:25270068
Kuipers J, Oosterhuis JK, Krijnen WP, et al. Prevalence of intradialytic hypotension, clinical symptoms and nursing interventions—a three-months, prospective study of 3818 haemodialysis sessions. BMC Nephrol. 2016;17(1):21. https://doi.org/10.1186/s12882-016-0231-9 PMID:26922795
Stefánsson BV, Brunelli SM, Cabrera C, et al. Intradialytic hypotension and risk of cardiovascular disease. Clin J Am Soc Nephrol. 2014;9(12):2124-2132. https://doi.org/10.2215/CJN.02680314 PMID:25376764
Sands JJ, Usvyat LA, Sullivan T, et al. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. Hemodial Int. 2014;18(2):415-422. https://doi.org/10.1111/hdi.12138 PMID:24467830
Chou JA, Streja E, Nguyen DV, et al. Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrol Dial Transplant. 2018;33(1):149-159. https://doi.org/10.1093/ndt/gfx037 PMID:28444336
Tislér A, Akócsi K, Borbás B, et al. The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant. 2003;18(12):2601-2605. https://doi.org/10.1093/ndt/gfg450 PMID:14605284
Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66(3):1212-1220. https://doi.org/10.1111/j.1523-1755.2004.00812.x PMID:15327420
Takashima H, Maruyama T, Abe M. Significance of levocarnitine treatment in dialysis patients. Nutrients. 2021;13(4):1219. https://doi.org/10.3390/nu13041219 PMID:33917145
Ibarra-Sifuentes HR, Del Cueto-Aguilera Á, Gallegos-Arguijo DA, et al. Levocarnitine decreases intradialytic hypotension episodes: a randomized controlled trial. Ther Apher Dial. 2017;21(5):459-464. https://doi.org/10.1111/1744-9987.12553 PMID:28805348
Kooman J, Basci A, Pizzarelli F, et al. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant. 2007;22(Suppl 2):ii22-ii44. https://doi.org/10.1093/ndt/gfm019PMID:17507425
K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4)(Suppl 3):S1-S153. PMID:15806502
Lynch KE, Feldman HI, Berlin JA, Flory J, Rowan CG, Brunelli SM. Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis. Am J Kidney Dis. 2008;52(5):962-971. https://doi.org/10.1053/j.ajkd.2008.05.031 PMID:18706751
Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004 May;43(5 Suppl 1):S1-290. PMID 15114537
Reilly RF. Attending rounds: a patient with intradialytic hypotension. Clin J Am Soc Nephrol. 2014;9(4):798-803. https://doi.org/10.2215/CJN.09930913 PMID:24385517
Kudoh Y, Aoyama S, Torii T, et al. Hemodynamic stabilizing effects of L-carnitine in chronic hemodialysis patients. Cardiorenal Med. 2013;3(3):200-207. https://doi.org/10.1159/000355016 PMID:24454315
Katalinic L, Krtalic B, Jelakovic B, Basic-Jukic N. The unexpected effects of L-carnitine supplementation on lipid metabolism in hemodialysis patients. Kidney Blood Press Res. 2018;43(4):1113-1120. https://doi.org/10.1159/000491807 PMID:30016788
Kim KY, Park HS, Kim JS, et al. Comparison of intradialytic blood pressure metrics as predictors of all-cause mortality. Clin Kidney J. 2021;14(12):2600-2605. https://doi.org/10.1093/ckj/sfab124 PMID:34950471
Copyright (c) 2022 Gli autori
Questo lavoro è fornito con la licenza Creative Commons Attribuzione - Non commerciale 4.0 Internazionale.
Gli autori che scelgono il Giornale di Clinica Nefrologica e Dialisi (GCND) per la pubblicazione dei propri contributi si impegnano ad utilizzare la licenza CC-BY-NC 4.0, che consente a terzi di riutilizzare l'articolo senza richiedere permesso purchè l'articolo sia correttamente citato e non sia utilizzato a scopi commerciali.